The purpose of this study is to evaluate clinical outcomes and adverse events of salvage treatment for locoregional recurrence of breast cancer. The main questions it aims to answer are: * Clinical outcomes after salvage treatment for locoregional recurrence * Adverse events and quality of life after salvage treatment for locoregional recurrence * Patient characteristics and treatment specifics which are related to the clinical outcomes and/or adverse events * Molecular signature associated with treatment resistance Participants will be assessed by multi-dimensional methods during and after radiation therapy: * Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination * Assessment for the adverse events according to CTCAE version 5.0 * Assessment for the molecular signature using residual tissue after pathologic diagnosis * Assessment for the quality of life using questionnaires (BREAST-Q)
Study Type
OBSERVATIONAL
Enrollment
190
Appropriate salvage treatment (surgery and/or radiation therapy) will be selected by the treating clinicians considering the disease status.
Samsung Medical Center
Seoul, South Korea
RECRUITINGProgression-free survival
The event for progression-free survival was defined as any disease progression or breast cancer-related death.
Time frame: 5 years from the initiation of the salvage therapy
Rate of adverse events
Adverse events related to the salvage therapy will be reported and incidence rate will be calculated.
Time frame: 5 years from the initiation of the salvage therapy
Locoregional failure rate
The event for locoregional failure rate was defined as recurrence in breast / chest wall or regional lymph node area.
Time frame: 5 years from the initiation of the salvage therapy
Cancer-specific survival
The event for cancer-specific survival was defined as death of the participant related to the breast cancer.
Time frame: 5 years from the initiation of the salvage therapy
Quality of life (BREAST-Q)
Quality of life of the participants will be evaluated according to the BREAST-Q™ questionnaires. Higher Q-Score indicates better quality of life.
Time frame: 5 years from the initiation of the salvage therapy
Breast cosmesis
Cosmesis of the breast will be evaluated according to Harvard/National Surgical Adjuvant Breast and Bowel Project (NSABP)/Radiation Therapy Oncology Group (RTOG) Breast Cosmesis grading scale. This is a 4-point scale (Excellent, Good, Fair, and Poor), and evaluated by the clinicians.
Time frame: 5 years from the initiation of the salvage therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.